These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 3736634)

  • 1. Efficacy of alpha 2-interferon against the common cold.
    Foy HM; Fox JP; Cooney MK
    N Engl J Med; 1986 Aug; 315(8):513-4. PubMed ID: 3736634
    [No Abstract]   [Full Text] [Related]  

  • 2. Prophylactic efficacy of intranasal alpha 2-interferon against rhinovirus infections in the family setting.
    Douglas RM; Moore BW; Miles HB; Davies LM; Graham NM; Ryan P; Worswick DA; Albrecht JK
    N Engl J Med; 1986 Jan; 314(2):65-70. PubMed ID: 3001518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of natural colds by contact prophylaxis with intranasal alpha 2-interferon.
    Hayden FG; Albrecht JK; Kaiser DL; Gwaltney JM
    N Engl J Med; 1986 Jan; 314(2):71-5. PubMed ID: 3001519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention from naturally acquired viral respiratory infection by interferon nasal spray.
    Saito H; Takenaka H; Yoshida S; Tsubokawa T; Ogata A; Imanishi F; Imanishi J
    Rhinology; 1985 Dec; 23(4):291-5. PubMed ID: 4081525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What dose of intranasal interferon for the common cold?
    Herzog C; Berger R; Fernex M; Friesecke K; Havas L; Just M; Dubach UC
    Lancet; 1986 May; 1(8489):1089-90. PubMed ID: 2871352
    [No Abstract]   [Full Text] [Related]  

  • 6. Intranasal interferon for contact prophylaxis against common cold in families.
    Herzog C; Just M; Berger R; Havas L; Fernex M
    Lancet; 1983 Oct; 2(8356):962. PubMed ID: 6138515
    [No Abstract]   [Full Text] [Related]  

  • 7. Intranasal interferon-alpha 2 prophylaxis of natural respiratory virus infection.
    Douglas RM; Albrecht JK; Miles HB; Moore BW; Read R; Worswick DA; Woodward AJ
    J Infect Dis; 1985 Apr; 151(4):731-6. PubMed ID: 2982972
    [No Abstract]   [Full Text] [Related]  

  • 8. Intranasal interferon (rIFN-alpha A, Ro 22-8181) for contact prophylaxis against common cold: a randomized, double-blind and placebo-controlled field study.
    Herzog C; Berger R; Fernex M; Friesecke K; Havas L; Just M; Dubach UC
    Antiviral Res; 1986 May; 6(3):171-6. PubMed ID: 3524441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha 2-interferon for the common cold.
    Enlow ML; Haley CJ
    Ann Pharmacother; 1992 Mar; 26(3):345-7. PubMed ID: 1554955
    [No Abstract]   [Full Text] [Related]  

  • 10. Intranasal interferon alpha 2 for prevention of rhinovirus infection and illness.
    Hayden FG; Gwaltney JM
    J Infect Dis; 1983 Sep; 148(3):543-50. PubMed ID: 6311914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The common cold--relief at last?
    Douglas RG
    N Engl J Med; 1986 Jan; 314(2):114-5. PubMed ID: 3941682
    [No Abstract]   [Full Text] [Related]  

  • 12. Prevention of experimental coronavirus colds with intranasal alpha-2b interferon.
    Turner RB; Felton A; Kosak K; Kelsey DK; Meschievitz CK
    J Infect Dis; 1986 Sep; 154(3):443-7. PubMed ID: 3016111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerance of intranasally applied recombinant leukocyte A interferon in normal volunteers.
    Samo TC; Greenberg SB; Couch RB; Quarles J; Johnson PE; Hook S; Harmon MW
    J Infect Dis; 1983 Sep; 148(3):535-42. PubMed ID: 6619578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal interferon-alpha 2b for seasonal prophylaxis of respiratory infection.
    Monto AS; Shope TC; Schwartz SA; Albrecht JK
    J Infect Dis; 1986 Jul; 154(1):128-33. PubMed ID: 3011917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerance and efficacy of intranasal administration of recombinant beta serine interferon in healthy adults.
    Sperber SJ; Levine PA; Innes DJ; Mills SE; Hayden FG
    J Infect Dis; 1988 Jul; 158(1):166-75. PubMed ID: 2839579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An effective dosage regimen for prophylaxis against rhinovirus infection by intranasal administration of HuIFN-alpha 2.
    Phillpotts RJ; Scott GM; Higgins PG; Wallace J; Tyrrell DA; Gauci CL
    Antiviral Res; 1983 Aug; 3(2):121-36. PubMed ID: 6312877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranasal interferon-alpha 2 for prevention of natural rhinovirus colds.
    Farr BM; Gwaltney JM; Adams KF; Hayden FG
    Antimicrob Agents Chemother; 1984 Jul; 26(1):31-4. PubMed ID: 6089652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasally applied recombinant leukocyte A interferon in normal volunteers. II. Determination of minimal effective and tolerable dose.
    Samo TC; Greenberg SB; Palmer JM; Couch RB; Harmon MW; Johnson PE
    J Infect Dis; 1984 Aug; 150(2):181-8. PubMed ID: 6381611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trials of interferon in respiratory infections in man.
    Greenberg SB; Harmon MW; Tyrrell DA; Scott GM
    Tex Rep Biol Med; 1981-1982; 41():549-54. PubMed ID: 6763365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of intranasally applied medication during a cold.
    Phillpotts RJ; Davies HW; Willman J; Tyrrell DA; Higgins PG
    Antiviral Res; 1984 Apr; 4(1-2):71-4. PubMed ID: 6742821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.